(A) Agilent Technologies, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(A) Agilent Technologies, Inc. Bundle
Visual. Strategic. Downloadable.
This Agilent Technologies, Inc. BCG Matrix helps you quickly see how the company’s products or business units may fit into Stars, Cash Cows, Question Marks, and Dogs for strategy and capital allocation. The page already shows a real preview of the actual analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report instantly.
Stars
LC-MS systems
Agilent Technologies, Inc.’s LC-MS systems fit a Star in its BCG Matrix: they serve fast-growing biopharma, proteomics, and regulated testing demand, while a large installed base drives repeat method-development and service pull-through. In FY2025, Agilent generated about $6.5 billion in revenue, and LC-MS stays central to its higher-margin analytical workflow mix.
ICP-MS instruments
ICP-MS is a Star for Agilent Technologies, Inc.: it serves elemental impurities, PFAS, environmental, and semiconductor testing, where demand stays strong as EPA PFAS limits tighten to 4 ppt for PFOA and PFOS and chip fabs need ultra-trace contamination control. Agilent’s FY2025 revenue was about $6.9 billion, backing this high-value platform. It is a major supplier in a niche with high margins and a sticky installed base.
GC-MS workflows
GC-MS workflows are a Star for Company Name because they serve food, environmental, forensics, and industrial QA labs that need trace-level and compliance testing. Agilent Technologies, Inc. reported FY2025 revenue above $6 billion, and its broad chromatography plus mass spectrometry stack helps it win bundled sales and keep adoption high.
Cell analysis solutions
Cell analysis is a Star for Agilent Technologies, Inc. because demand is rising in immunology, cell therapy, and translational research. Agilent’s flow cytometers, real-time cell analyzers, and imaging tools fit higher-end workflows, so they can support premium pricing and recurring consumable pull-through. This space should keep growing as labs need faster, more precise live-cell data.
- Strong demand from cell therapy
- Supports high-value workflows
- Builds on Agilent’s life science base
Biopharma analytical workflows
Biopharma analytical workflows are a Star because R&D and QC need linked steps, not stand-alone tools. Agilent spans separation, detection, sample prep, and software, which fits regulated labs; Agilent reported FY2025 revenue of about $6.5 billion, and this workflow-led demand helps defend that base.
- Multi-step use beats single-instrument selling.
- Integrated lab fits support sticky regulated demand.
Agilent’s Star Platforms Power Growth, Margin Protection, and Lab Upgrades
Agilent Technologies, Inc. Stars include LC-MS, ICP-MS, GC-MS, cell analysis, and biopharma workflows: these are high-growth, high-value niches with sticky installed bases and strong pull-through. FY2025 revenue was about $6.5 billion, and these platforms help protect mix and margins as labs keep upgrading.
| Star | Why it fits | FY2025 signal |
|---|---|---|
| LC-MS | Biopharma and proteomics demand | Large workflow pull-through |
| ICP-MS | PFAS and trace metals testing | High-value regulated use |
| GC-MS | Compliance and QA labs | Broad installed base |
What is included in the product
Detailed Word Document
Agilent’s BCG Matrix shows which units to invest in, hold, or divest across Stars, Cash Cows, Question Marks, and Dogs.
Editable Excel File
One-page Agilent BCG Matrix clarifying portfolio priorities and easing strategic decisions
Reference Sources
Gives a credible source trail for Agilent Technologies, Inc., helping decision-makers verify assumptions fast and trust the analysis.
Cash Cows
LC systems
LC systems fit Cash Cows because liquid chromatography is a mature lab market with a large installed base and steady replacement demand. Agilent Technologies, Inc. keeps revenue stable through method continuity, service, and consumables, while its Life Sciences and Applied Markets unit still drives most of the company’s ~$6.5 billion fiscal 2025 revenue base. That makes Agilent a leading routine-lab vendor with predictable, repeat repeat sales.
GC systems
Agilent Technologies, Inc. reported FY2025 revenue of about $6.98 billion, and GC systems stayed a mature line inside its lab-testing portfolio. Gas chromatography is still a core QC tool in pharma, food, and environmental labs, so the large installed base keeps consumables and service demand steady. Growth is slower than omics tools, but that installed base makes GC a dependable cash generator.
Columns and sample prep consumables
Columns and sample prep consumables are a cash cow because they get replaced again and again as Agilent’s installed base keeps running. Agilent reported $6.51 billion in FY2024 revenue, and this recurring stream usually carries higher margins than hardware. CrossLab strengthens that annuity-like demand by tying consumables, services, and support to instrument use.
CrossLab service contracts
CrossLab service contracts fit the Cash Cows box because they are recurring, tied to instruments already in customer labs, and less dependent on new market growth. Agilent Technologies, Inc. reported FY2025 revenue near $6.8 billion, and this installed-base model keeps cash flow steady through service, startup support, compliance, and asset management.
- Recurring revenue from the installed base
- Low growth need, steady cash generation
- Supports labs after instrument sale
- Boosts retention and lifetime value
Routine lab software and maintenance
Routine lab software and maintenance is a classic Cash Cow for Agilent Technologies, Inc. Installed-base tools and service contracts keep labs running, so customers pay for upgrades, validation, and uptime instead of frequent new buys. That creates steady, low-growth cash with high renewal value.
- Recurring support beats new unit sales
- Uptime and validation drive renewals
- Stable cash, low capital need
Agilent Technologies, Inc. also benefits from a large installed base across analytical labs, which makes this stream sticky and defensive.
Agilent’s Cash Cows: Recurring Lab Revenue Powers FY2025
Agilent Technologies, Inc.’s Cash Cows are its installed-base businesses: LC and GC systems, columns, sample prep, CrossLab service, and routine software support. FY2025 revenue was about $6.98 billion, and these lines stay strong because labs replace consumables and renew service, not just buy new tools.
| Cash cow | Why it fits | FY2025 signal |
|---|---|---|
| LC, GC, CrossLab | Recurring installs and renewals | About $6.98B revenue |
What You See Is What You Get
Agilent Technologies, Inc. Reference Sources
This preview shows the same Agilent Technologies, Inc. BCG Matrix document you’ll receive after purchase. No sample pages or demo content—just the full, ready-to-use report. Download the exact file instantly and use it for analysis, presentations, or planning.
Dogs
Atomic absorption (AA)
Atomic absorption is a legacy elemental analysis tool, and it fits the Dogs bucket because adoption has lagged ICP-MS and ICP-OES. It still has a place in some labs for routine single-element work, but growth is thin and replacement risk is high. Agilent’s FY2025 spending and product focus remain centered on newer, higher-throughput platforms, not AA.
MP-AES
MP-AES is a niche elemental-analysis tool, so it fits Agilent Technologies, Inc. as a Dogs/low-share, low-growth asset in the BCG Matrix. It trails ICP-based methods, which dominate the broader inorganic analysis market and keep most growth in higher-end platforms. That makes MP-AES less central to Agilent Technologies, Inc.’s core growth story and more of a maintenance product than a scale driver.
Legacy DNA microarrays
Legacy DNA microarrays sit in the Dogs quadrant for Agilent Technologies, Inc. because the platform is mature and has been displaced by next-generation sequencing. Agilent’s FY2025 base is now centered on higher-growth genomics tools, while microarrays face structurally weaker demand as labs shift to sequencing-first workflows. That leaves this franchise low-growth, lower-priority, and mainly a cash harvest play.
H&E and older ISH staining lines
H&E and older ISH staining lines sit in a mature, crowded pathology market, so volume grows slowly and pricing power is limited. Agilent’s FY2025 mix still favors faster tools like molecular diagnostics and sequencing, while legacy stains face stronger competition from large, established lab suppliers. This makes the unit a classic Dog in the BCG Matrix: low growth, modest share, and weak differentiation.
- Mature market, slower growth
- Limited tech edge versus newer assays
- Low BCG Matrix attractiveness
Non-core vacuum and general measurement products
Agilent Technologies, Inc.’s non-core vacuum and general measurement products sit outside its chromatography and genomics engines, so they usually act more like cash-drain or maintenance lines than growth drivers. Agilent reported FY2025 revenue of about $6.7 billion, but it does not break out these smaller products separately, which itself signals their limited strategic weight.
- Peripheral, not core
- Low growth, more commoditized
- Not a main expansion engine
Agilent’s Dog Lines Are Legacy Cash Harbors, Not Growth Engines
Dogs in Agilent Technologies, Inc. stay tied to legacy, low-growth lines like atomic absorption, MP-AES, DNA microarrays, and older H&E/ISH stains. They face displacement from ICP-based tools, next-gen sequencing, and newer pathology workflows, so FY2025 capital and product focus stayed on higher-growth platforms. These lines look more like cash-harvest assets than growth engines.
| Dog line | 2025 signal | BCG view |
|---|---|---|
| Atomic absorption | Legacy, lagging adoption | Low growth, low share |
| MP-AES | Niche vs ICP methods | Maintenance asset |
| DNA microarrays | Sequencing displacement | Cash harvest |
| H&E/older ISH | Mature pathology market | Weak differentiation |
Question Marks
Target enrichment for NGS
Target enrichment for NGS sits in a growing market, but share is still hard to win. Agilent Technologies, Inc. plays here through enrichment workflows and software, while the broader NGS market was about $15.5 billion in 2025 and is still expanding at high single digits. The category is a question mark, so Agilent likely needs more investment to scale share against fierce rivals.
Liquid-based pharmacodiagnostics
Liquid-based pharmacodiagnostics fits the Question Marks box: it is a developing diagnostics area with clear upside, but current market share is still likely small. Agilent Technologies, Inc. has treated adjacent diagnostics and lab workflow tools as growth bets, even though its fiscal 2024 revenue was $6.51 billion, showing the group still has scale but this niche is early-stage. If adoption rises, it can grow fast; if not, it may stay a low-share bet.
Lab automation and robotics
Lab automation and robotics look like a Question Mark for Agilent Technologies, Inc.: demand is rising in life sciences and applied labs, but the field is crowded with specialists. Agilent generated $6.51 billion in fiscal 2024 revenue, yet this niche still needs more spend to win share. Stronger products, service, and software will decide if it becomes a Star or stays a small bet.
SaaS lab informatics
SaaS lab informatics fits BCG Question Mark for Agilent Technologies, Inc.: cloud lab software is growing fast as labs digitize workflows, but competition is still crowded and Agilent does not show clear share dominance. Agilent Technologies, Inc. has broad data management and analytics tools, yet this line looks like a build-or-buy bet, not a cash cow.
- High growth, unclear share
- Strong digitization tailwind
- Competitive market pressure
- Needs scale to win
Advanced imaging systems
Advanced imaging systems are a Question Mark for Agilent Technologies, Inc. because cell biology and translational research demand is rising, but the field is crowded with Leica, Zeiss, Nikon, and Thermo Fisher. FY2025 peer spending stayed heavy on R&D, so the upside is real, but Agilent still has to win share, not just ride demand. Growth can be strong, yet market position remains the key test.
- Growing demand, but tough peer set
- Share gains matter more than category growth
Agilent’s Question Marks: Big 2025 Markets, But Share Still Up for Grabs
Question Marks need capital but still lack clear share. In Agilent Technologies, Inc., NGS target enrichment, lab automation, SaaS informatics, and advanced imaging sit in 2025 growth markets, yet rivals still control much of the share. The 2025 NGS market was about $15.5 billion, so the upside is real, but Agilent must spend to win.
| Area | 2025 view | BCG fit |
|---|---|---|
| NGS enrichment | $15.5B market | Question Mark |
| Automation | High growth, crowded | Question Mark |
| Lab SaaS | Fast digitization | Question Mark |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.